Author Correction: Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer

Paolo Tarantino^#^{1

2

3

4}, Hersh Gupta^#^{5

6}, Melissa E Hughes⁵, Janet Files⁵, Sarah Strauss⁵, Gregory Kirkner⁵, Anne-Marie Feeney⁵, Yvonne Li⁵, Ana C Garrido-Castro^{5

7

8}, Romualdo Barroso-Sousa^{9

10}, Brittany L Bychkovsky^{7

8

11}, Simona DiLascio⁵, Lynette Sholl⁵, Laura MacConaill⁵, Neal Lindeman^{5

12}, Bruce E Johnson⁵, Matthew Meyerson^{5

8

6}, Rinath Jeselsohn^{5

7

8}, Xintao Qiu⁵, Rong Li⁵, Henry Long⁵, Eric P Winer¹³, Deborah Dillon^{8

14}, Giuseppe Curigliano¹⁵, Andrew D Cherniack^{5

8

6}, Sara M Tolaney^{5

7

8}, Nancy U Lin^{5

7

8}

Affiliations

¹ Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. paolo_tarantino@dfci.harvard.edu.
² Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA. paolo_tarantino@dfci.harvard.edu.
³ Harvard Medical School, Boston, MA, USA. paolo_tarantino@dfci.harvard.edu.
⁴ Department of Oncology and Hematology-Oncology, University of Milano, Milano, Italy. paolo_tarantino@dfci.harvard.edu.
⁵ Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
⁶ Broad Institute of Harvard and MIT, Cambridge, MA, USA.
⁷ Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
⁸ Harvard Medical School, Boston, MA, USA.
⁹ Dasa Institute for Education and Research (IEPD), Brasilia, Brazil.
¹⁰ Dasa Oncology/Hospital Brasilia, Brasilia, Brazil.
¹¹ Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA, USA.
¹² Department of Pathology, Weill Cornell Medicine, New York, NY, USA.
¹³ Yale Cancer Center, Yale School of Medicine, Smilow Cancer Hospital, New Haven, CT, USA.
¹⁴ Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
¹⁵ Division of Early Drug Development, European Institute of Oncology IRCCS, Milano, Italy.

^# Contributed equally.

Published Erratum

Paolo Tarantino et al. Nat Commun. 2023.

. 2023 Dec 14;14(1):8321.

doi: 10.1038/s41467-023-44124-y.

¹ Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. paolo_tarantino@dfci.harvard.edu.
² Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA. paolo_tarantino@dfci.harvard.edu.
³ Harvard Medical School, Boston, MA, USA. paolo_tarantino@dfci.harvard.edu.
⁴ Department of Oncology and Hematology-Oncology, University of Milano, Milano, Italy. paolo_tarantino@dfci.harvard.edu.
⁵ Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
⁶ Broad Institute of Harvard and MIT, Cambridge, MA, USA.
⁷ Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
⁸ Harvard Medical School, Boston, MA, USA.
⁹ Dasa Institute for Education and Research (IEPD), Brasilia, Brazil.
¹⁰ Dasa Oncology/Hospital Brasilia, Brasilia, Brazil.
¹¹ Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA, USA.
¹² Department of Pathology, Weill Cornell Medicine, New York, NY, USA.
¹³ Yale Cancer Center, Yale School of Medicine, Smilow Cancer Hospital, New Haven, CT, USA.
¹⁴ Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
¹⁵ Division of Early Drug Development, European Institute of Oncology IRCCS, Milano, Italy.

^# Contributed equally.

No abstract available

Erratum for

Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer.
Tarantino P, Gupta H, Hughes ME, Files J, Strauss S, Kirkner G, Feeney AM, Li Y, Garrido-Castro AC, Barroso-Sousa R, Bychkovsky BL, DiLascio S, Sholl L, MacConaill L, Lindeman N, Johnson BE, Meyerson M, Jeselsohn R, Qiu X, Li R, Long H, Winer EP, Dillon D, Curigliano G, Cherniack AD, Tolaney SM, Lin NU. Tarantino P, et al. Nat Commun. 2023 Nov 18;14(1):7496. doi: 10.1038/s41467-023-43324-w. Nat Commun. 2023. PMID: 37980405 Free PMC article.